Loading resource…

American College of Cardiology Foundation
Paradoxical low-flow, low-gradient aortic stenosis has a worse prognosis than other aortic stenosis subtypes. This trial aims to determine if TAVR, when added to OMT, can reduce all-cause mortality in symptomatic patients with this condition. The study is a multicenter, open-label trial that randomly assigned patients to receive either TAVR plus OMT or OMT alone, with a primary endpoint of all-cause death assessed two years post-enrollment.
No account needed